27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
White matter hyperintensities are associated with an increased risk of all-dementia and Alzheimer's disease in the general population. 3 key findings →
Design: meta-analysis Participants: 3,913 Evidence: high
Full summary, score breakdown and related studies → Original source
The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia. 3 key findings →
Design: cohort study Participants: 6,989 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The diabetes attributable risk for dementia of 8.8% suggests that diabetes may have contributed to the clinical syndrome in a substantial proportion of all dementia patients. 2 key findings →
Design: cohort study Participants: 126 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High dietary intake of vitamin C and vitamin E may lower the risk of Alzheimer disease. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is one of the most heritable diseases in elderly people and the most common type of dementia. 4 key findings →
Design: cohort study Participants: 926 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The APOE genotype is an important determinant of the risk of dementia. 1 key finding →
Design: cohort study Participants: 134 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the 1990 subcohort (25,696 person-years), 286 persons developed dementia, and in the 2000 subcohort (8,384 person-years), 49 persons. 4 key findings →
Design: cohort study Participants: 5,727 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In elderly hypertensive patients, a slightly more effective blood pressure reduction during candesartan-based therapy, compared with control therapy, was associated with a modest, statistically non-significant, reduction in major cardiovascular events and with a marked reduction in non-fatal stroke. 4 key findings →
Design: open-label trial Participants: 4,964 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High concentrations of Abeta(1-40) but not Abeta(1-42) at baseline were associated with an increased risk of dementia. 5 key findings →
Design: cohort study Participants: 6,713 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During mean follow-up of 2.1 (range 1.5-3.4) years, 146 incident cases of dementia were detected, of which 105 were Alzheimer's disease. 3 key findings →
Design: case-control study Participants: 6,870 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cerebral hypoperfusion has previously been associated with mild cognitive impairment and dementia in various cross-sectional studies, but whether hypoperfusion precedes neurodegeneration is unknown. 4 key findings →
Design: cross-sectional Participants: 4,759 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We re-assessed after longer follow-up time in the large population-based cohort of the Rotterdam Study whether smoking habits and pack-years of smoking are associated with the risk of dementia, Alzheimer disease (AD), and vascular dementia (VaD). 4 key findings →
Design: cohort study Participants: 6,868 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A substantial proportion of the relationship between education and dementia was mediated through mid-life vascular risk factors. 2 key findings →
Design: cohort Participants: 13,368 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that insulin metabolism influences the clinical manifestation of AD only within 3 years. 5 key findings →
Design: cohort study Participants: 3,139 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High intake of total, saturated, and trans fat and cholesterol and low intake of MUFA, PUFA, n-6 PUFA, and n-3 PUFA were not associated with increased risk of dementia or its subtypes. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Atrial fibrillation (AF) has been suggested as a risk factor for dementia since it may lead to chronic cerebral hypoperfusion and stroke. 4 key findings →
Design: longitudinal study Participants: 6,514 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
To assess age-, sex-, and subtype-specific incidence rates of dementia and to calculate the risk of dementia, the authors performed a large, community-based, prospective cohort study on dementia as part of the Rotterdam Study. 4 key findings →
Design: cohort study Participants: 7,046 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Atherosclerosis has been implicated in the development of dementia and its major subtypes, Alzheimer's disease and vascular dementia. 4 key findings →
Design: cohort study Participants: 6,647 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Rotterdam Study previously found that higher dietary intakes of vitamins E and C related to lower risk of dementia and Alzheimer disease (AD) over 6 years of follow-up. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Vascular and inflammatory factors may play an important role in the pathogenesis of dementia. 4 key findings →
Participants: 2,835 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The direct visualization of retinal vessels provides a unique opportunity to study cerebral small vessel disease, because these vessels share many features. 2 key findings →
Design: cohort study Participants: 490 Evidence: moderate
Full summary, score breakdown and related studies → Original source
White matter lesions are frequently found on cerebral MRI scans of elderly people and are thought to be important in the pathogenesis of dementia. 5 key findings →
Design: cross-sectional Participants: 1,077 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
White matter lesions, especially in the periventricular region, increase the risk of dementia in elderly people. 2 key findings →
Design: cohort study Participants: 1,077 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We examined whether cognitive function at baseline affected cognitive and cardiovascular outcomes in the Study on COgnition and Prognosis in the Elderly (SCOPE), a blood pressure (BP)-lowering intervention trial. 4 key findings →
Design: open-label trial Participants: 2,070 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our results provide further indirect support for the presumed link between superficial siderosis and cerebral amyloid angiopathy (CAA). 2 key findings →
Design: longitudinal study Participants: 1,062 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →